GlassScriptPhysician profile
Reena M Matthews
NPI 1932665536
$3,722.09
in general payments reported to CMS, 2019-2025
24 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.76 · 2022: $279 · 2023: $1,175 · 2024: $1,092 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,057 · Education: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,056.52 |
| Education | $325.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $530.10 | 2022-2025 | Xospata, Cresemba |
| Incyte Corporation | $431.35 | 2021-2025 | Jakafi |
| Lilly USA, LLC | $418.67 | 2023-2025 | Jaypirca |
| Celgene Corporation | $288.92 | 2022-2025 | Reblozyl |
| Sobi, INC | $243.89 | 2024-2025 | |
| Pharmaessentia USA Corporation | $208.08 | 2023-2024 | Besremi |
| Novartis Pharmaceuticals Corporation | $207.11 | 2022-2025 | |
| Syndax Pharmaceuticals, INC. | $189.47 | 2025 | |
| Cti Biopharma Corp. | $185.78 | 2022-2023 | Vonjo |
| Astrazeneca Pharmaceuticals LP | $155.05 | 2023-2025 | Calquence |
| Beigene USA, INC. | $132.38 | 2024 | Brukinsa |
| Abbvie INC. | $131.70 | 2021-2025 | |
| Janssen Biotech, INC. | $124.09 | 2022-2023 | Imbruvica |
| Mirati Therapeutics, INC. | $113.63 | 2023 | Krazati |
| Daiichi Sankyo INC. | $82.89 | 2023-2024 | Vanflyta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.34 | 2023-2025 | Recarbrio, Zerbaxa, Dificid |
| Servier Pharmaceuticals LLC | $49.63 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $31.60 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Glaxosmithkline, LLC. | $30.06 | 2024 | Ojjaara |
| Amgen INC. | $28.31 | 2023 | Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $26.52 | 2024 | Iclusig |
| Pharmacyclics LLC, An Abbvie Company | $24.27 | 2023 | Imbruvica, Epkinly |
| Smith+Nephew, INC. | $15.73 | 2024 | Grafix Pl, Oasis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.